From: SOXs in human prostate cancer: implication as progression and prognosis factors
Clinical features (Numbers) | SOX7 | SOX9 | SOX10 | |||
---|---|---|---|---|---|---|
IRS | P | IRS | P | IRS | P | |
X̅ ± s |  | X̅ ± s |  | X̅ ± s |  | |
Age (years) | ||||||
< 70 (75) | 3.93 ± 0.219 | 0.530 | 7.46 ± 0.268 | 0.114 | 2.73 ± 0.215 | 0.875 |
≥70 (72) | 4.14 ± 0.224 | 6.68 ± 0.403 | 2.79 ± 0.295 | |||
Serum PSA Levels (ng/ml) | ||||||
<4 (27) | 4.50 ± 0.330 | 0.021 | 7.17 ± 0.560 | 0.968 | 3.29 ± 0.456 | 0.025 |
≥4 (120) | 3.34 ± 0.183 | 7.14 ± 0.251 | 2.33 ± 0.185 | |||
Gleason Score | ||||||
< 8 (118) | 4.09 ± 0.183 | 0.317 | 5.93 ± 0.606 | 0.024 | 2.66 ± 0.188 | 0.276 |
≥8 (29) | 3.69 ± 0.322 | 7.46 ± 0.235 | 3.14 ± 0.438 | |||
Clinical Stage | ||||||
<T2A(79) | 3.95 ± 0.205 | 0.431 | 6.39 ± 0.326 | <0.001 | 2.62 ± 0.226 | 0.498 |
≥T2A(68) | 4.21 ± 0.259 | 8.25 ± 0.270 | 2.86 ± 0.269 | |||
Pathological Stage | ||||||
T2A-T2C(86) | 4.06 ± 0.209 | 0.742 | 7.23 ± 0.282 | 0.693 | 3.53 ± 0.214 | 0.013 |
T3A-T4(61) | 3.95 ± 0.249 | 7.05 ± 0.381 | 2.27 ± 0.287 | |||
Metstasis | ||||||
No (119) | 4.88 ± 0.179 | 0.025 | 7.34 ± 0.240 | 0.104 | 2.67 ± 0.186 | 0.327 |
Yes (28) | 3.75 ± 0.359 |  | 6.39 ± 0.611 |  | 3.11 ± 0.455 |  |